ArticleInternational journal of clinical and experimental pathology2025
Correlation between the type of esophagogastric junction and refractory reflux esophagitis.
Article in International journal of clinical and experimental pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the correlation between refractory gastroesophageal reflux disease (RGERD) and the esophagogastric junction (EGJ), as well as to assess their effect on the efficacy of acid suppression therapy.
methodsThis prospective cohort study (ChiCTR2500101077) enrolled 81 patients with reflux esophagitis (RE) at Pingxiang People's Hospital from April 2023 to September 2024. Participants underwent high-resolution manometry (HRM) to classify EGJ subtypes (I-III) and received an 8-week course of vonorasen fumarate therapy. Refractory reflux esophagitis (RRE) was defined as the persistence of GERD-Q symptoms following treatment. Patients diagnosed with RRE underwent 24-hour pH-impedance monitoring to evaluate the efficacy of acid suppression.
resultsThe EGJ subtypes were classified as Type I (n=44), Type II (n=21), and Type III (n=16). After treatment, 37 patients were diagnosed with RRE, including 13 cases of Type I, 12 cases of Type II, and 12 cases of Type III, with significant differences observed among the three groups (P<0.004). The EGJ subtype negatively correlated with LES pressure (r=-0.626, P<0.001). 24 h-pH impedance monitoring demonstrated significant differences in reflux metrics, including total reflux episodes (P<0.001), acid exposure percentage (P<0.001), prolonged reflux episodes (P<0.003), and DeMeester score (P<0.001) among the EGJ subtypes, with correlation coefficients of 0.800, 0.787, 0.489, and 0.800, respectively.
conclusionEGJ type significantly influences the development of RRE, with Type III EGJ exhibiting the strongest association. An abnormal EGJ structure reduces LES pressure and increases acid exposure, thereby diminishing the efficacy of acid suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.